EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials

Sarah Kim iD, Rebecca J Willcocks, Michael J Daniels, Juan Francisco Morales, Deok Yong Yoon, William T Triplett, Alison M Barnard, Daniela J Conrado, Varun Aggarwal iD, Ramona Belfiore-Oshan, Terina N Martinez, Glenn A Walter und 2 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2023-10 · 12 (10) · 1437-1449

DOI: 10.1002/psp4.13021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 27.08.2023. Verfasst von Sarah Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although regulatory agencies encourage inclusion of imaging biomarkers in clinical trials for Duchenne muscular dystrophy (DMD), industry receives minimal guidance on how to use these biomarkers most beneficially in trials. This study aims to identify the optimal use of muscle fat fraction biomarkers in DMD clinical trials through a quantitative disease‐drug‐trial modeling and simulation approach. We simultaneously developed two multivariate models quantifying the longitudinal associations between 6‐minute walk distance (6MWD) and fat fraction measures from vastus lateralis and soleus muscles. We leveraged the longitudinal individual‐level data collected for 10 years through the ImagingDMD study. Age of the individuals at assessment was chosen as the time metric. After the longitudinal dynamic of each measure was modeled separately, the selected univariate models were combined using correlation parameters. Covariates, including baseline scores of the measures and steroid use, were assessed using the full model approach. The nonlinear mixed‐effects modeling was performed in Monolix. The final models showed reasonable precision of the parameter estimates. Simulation‐based diagnostics and fivefold cross‐validation further showed the model's adequacy. The multivariate models will guide drug developers on using fat fraction assessment most efficiently using available data, including the widely used 6MWD. The models will provide valuable information about how individual characteristics alter disease trajectories. We will extend the multivariate models to incorporate trial design parameters and hypothetical drug effects to inform better clinical trial designs through simulation, which will facilitate the design of clinical trials that are both more inclusive and more conclusive using fat fraction biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneHumansMagnetic Resonance SpectroscopyMagnetic Resonance ImagingBiomarkersOutcome Assessment, Health Care

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.
  • Department of Statistics, University of Florida, Gainesville, Florida, USA.
  • e-Quantify LLC, La Jolla, California, USA.
  • Critical Path Institute, Tucson, Arizona, USA.
  • Department of Physiology and Aging, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Sarah Kim, Varun Aggarwal

Förderung

  • NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIAMS NIH HHS
  • NICHD NIH HHS
  • National Institutes of Health

Zitieren

APA

Kim, S., Willcocks, R. J., Daniels, M. J., Morales, J. F., Yoon, D. Y., Triplett, W. T., Barnard, A. M., Conrado, D. J., Aggarwal, V., Belfiore-Oshan, R., Martinez, T. N., Walter, G. A., Rooney, W. D., & Vandenborne, K. (2023). Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT: Pharmacometrics & Systems Pharmacology, 12(10), 1437-1449. https://doi.org/10.1002/psp4.13021

Vancouver

Kim S, Willcocks RJ, Daniels MJ, Morales JF, Yoon DY, Triplett WT, et al. Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(10):1437-1449. doi:10.1002/psp4.13021

BibTeX
@article{Kim2023,
  author = {Kim, Sarah and Willcocks, Rebecca J and Daniels, Michael J and Morales, Juan Francisco and Yoon, Deok Yong and Triplett, William T and Barnard, Alison M and Conrado, Daniela J and Aggarwal, Varun and Belfiore-Oshan, Ramona and Martinez, Terina N and Walter, Glenn A and Rooney, William D and Vandenborne, Krista},
  title = {Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {1437--1449},
  doi = {10.1002/psp4.13021}
}
Kostenlos starten →